🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

493 results for “Regeneron UK Limited” Clear

  1. REGN3918

    Regeneron UK Limited

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  2. REGN421(SAR153192)

    Regeneron UK Limited

    Advanced Solid Malignancies

    phase 1 small molecule completed

    1 trial

  3. REGN4461

    Regeneron UK Limited

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  4. REGN4659

    Regeneron UK Limited

    Carcinoma, Non-Small-Cell Lung

    phase 1 small molecule terminated

    1 trial

  5. REGN475 (SAR164877)

    Regeneron UK Limited

    Healthy

    phase 1 mab completed

    1 trial

  6. REGN5069

    Regeneron UK Limited

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  7. REGN5093-M114

    Regeneron UK Limited

    Advanced NSCLC

    phase 1 small molecule terminated

    1 trial

  8. REGN5381

    Regeneron UK Limited

    Healthy

    phase 1 small molecule completed

    1 trial

  9. REGN5678

    Regeneron UK Limited

    Prostate Cancer

    phase 1 small molecule active

    1 trial

  10. REGN5713-5714-5715

    Regeneron UK Limited

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  11. REGN6490

    Regeneron UK Limited

    Healthy Volunteer

    phase 1 small molecule terminated

    2 trials

  12. REGN6569

    Regeneron UK Limited

    Squamous Cell Carcinoma of Head and Neck

    phase 1 small molecule terminated

    1 trial

  13. REGN668

    Regeneron UK Limited

    Dermatitis

    phase 1 mab completed

    1 trial

  14. REGN668

    Regeneron UK Limited

    Healthy

    phase 1 mab completed

    1 trial

  15. REGN668: Injection Rate 1

    Regeneron UK Limited

    Healthy

    phase 1 small molecule completed

    1 trial

  16. REGN7257

    Regeneron UK Limited

    Severe Aplastic Anemia (SAA)

    phase 1 small molecule terminated

    1 trial

  17. REGN727

    Regeneron UK Limited

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  18. REGN727

    Regeneron UK Limited

    Healthy

    phase 1 small molecule completed

    1 trial

  19. REGN727(SAR236553)

    Regeneron UK Limited

    Hypercholesterolemia

    phase 1 small molecule completed

    1 trial

  20. REGN728

    Regeneron UK Limited

    Healthy

    phase 1 mab completed

    1 trial

  21. REGN7508 (IV)

    Regeneron UK Limited

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  22. REGN7544

    Regeneron UK Limited

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  23. REGN7999

    Regeneron UK Limited

    Healthy

    phase 1 small molecule completed

    1 trial

  24. REGN846

    Regeneron UK Limited

    Healthy

    phase 1 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources